Coya Therapeutics Reports Results for Quarter Ended June 30, 2026

What Happened Coya Therapeutics, Inc. announced on August 11, 2026 that it furnished a press release disclosing its results of operations for the fiscal quarter ended June 30, 2026. The disclosure was made via a Form 8-K (Item 2.02) and the press release is furnished as Exhibit 99.1 to the filing. The Form 8-K was signed by CEO Arun Swaminathan, Ph.D.

Key Details

• Filing date: August 11, 2026 (Form 8-K furnished to the SEC).
• Topic reported: results of operations for the fiscal quarter ended June 30, 2026 (Item 2.02).
• Exhibit included: Exhibit 99.1 — Press Release dated August 11, 2026.
• Form execution: Signed by Arun Swaminathan, Ph.D., Chief Executive Officer.

Why It Matters This 8-K makes the company’s recent quarterly results publicly available; the press release likely contains the specific financial metrics (revenue, earnings/loss, cash position) and operational updates investors monitor. Retail investors should read Exhibit 99.1 (the press release) and other SEC filings for the detailed figures and any commentary on guidance or cash runway to assess the company’s financial trend and outlook.